Summary of ceftaroline fosamil clinical trial studies and clinical safety (Q38035807)

27 August 2017

Summary of ceftaroline fosamil clinical trial studies and clinical safety (English)

1 reference

27 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

2

Mark H Wilcox

0 references

Thomas M. File

series ordinal

1

object named as

Thomas M File

1 reference

27 August 2017

Gary E Stein

3

1 reference

PubMed ID

22903949

27 August 2017

language of work or name

English

0 references

publication date

1 September 2012

1 reference

Clinical Infectious Diseases

27 August 2017

1 reference

27 August 2017

55 Suppl 3

1 reference

27 August 2017

S173-80

1 reference

Burden of community-acquired pneumonia in North American adults

27 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

21 January 2018

Cephalosporin allergy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Effect of ceftaroline on normal human intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Potential for bleeding with the new beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

Hepatotoxicity of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS559

21 January 2018

Identifiers

DOI

10.1093/CID/CIS559

1 reference

27 August 2017

1 reference

PubMed ID

22903949